The Ozempic Stock Hangover – What Happens to Novo Nordisk When Everyone Else Catches Up

Nearly nobody on Wall Street would have placed a wager against Novo Nordisk a year ago. The Danish pharmaceutical company had discreetly transformed a substance known as semaglutide into something more akin to cultural furniture than a prescription. In taxis, you heard the jingle. You saw the advertisements on stadium boards in New Jersey and at bus shelters in Toronto. Oprah brought it up. Elon Musk made a joke about it. Ozempic ceased to be medicine and turned into a verb somewhere between an Oscar joke and a conversation in a Costco parking lot. Then came the hangover.

Novo Nordisk informed investors on a gloomy Monday in late November that the long-shot Alzheimer’s trial had not slowed cognitive decline. Already damaged, the stock fell about 10% in the morning and lumbered toward a four-year low. In retrospect, the company’s chief scientific officer’s description of the wager as a lottery ticket sounds less like humility and more like a warning that the market chose to ignore. It’s not tragic to lose a lottery ticket. It’s not the same as losing it while the rest of your business softens.

Observing a company this powerful falter has an odd quality. Not only is Novo Nordisk well-known in Denmark. In some ways, it’s practically Denmark’s economy. Its Bagsvaerd campus, with its clipped hedges and modernist glass, has long been a destination for investors and health journalists. However, since January, the share price has dropped by almost half due to pressure from slowing sales growth, guidance cuts, a change in the CEO, and the unpleasant introduction of Eli Lilly’s Mounjaro and Zepbound, which doctors and patients increasingly view as interchangeable, even preferable.

The trial’s failure is not the deeper issue. It’s the math of a once seemingly infinite market. Ozempic was a tiny, odd medication with a devoted diabetic fan base when it first came out. The culture discovered it somewhere along the route. Medi-spas offered compounded versions. Prescriptions were transformed into subscription services by telehealth firms. Once a far-off issue, generic pressure is now in the near future. There will be less expensive versions soon. Prices are being pushed down by governments. Rarely did the Biden and Trump administrations agree that Americans should pay less for the medication. That alignment is uncommon and illuminating.

Though no one seems very certain, investors appear to think Novo Nordisk will stabilize. Following the Alzheimer’s readout, Jeffrey’s analysts employed cautious language that conveys disappointment while maintaining a professional demeanor. The stock had already been downgraded by Morgan Stanley in September. It’s difficult to ignore how abruptly the story changed from unstoppable to frail.

Even so, there is something about the business that seems resilient. Semaglutide fostered genuine allegiance. There is still water in the pipeline. Denmark has real manufacturing power. It’s possible that this is a reset rather than a decline, the equivalent in the industry of a celebrity taking a year off before coming back more disciplined, leaner, and less hyped.

Beneath the financial narrative is another, more subdued question. What happens to a company that staked its future on a culture’s desire for a particular product, and what happens to a culture that built its thinness on that product? You get the impression that neither side intended for this to be ordinary as you watch it play out. Novo Nordisk is discovering that miracles, which were formerly inexpensive and widespread, have changed completely.